Quarterly ResultMay 11, 2026, 04:07 PM
Ceribell Q1 Revenue +29% to $26.5M; Raises FY26 Guidance
AI Summary
Ceribell reported strong financial results for the first quarter ended March 31, 2026, with total revenue increasing 29% year-over-year to $26.5 million. The company also raised its full-year 2026 revenue guidance to a range of $112 million to $116 million, representing 26% to 30% growth. Key operational achievements include the commercial launch of neonate and pediatric products and a supportive CMS proposed rule for NTAP reimbursement for its delirium monitoring solution, with the final rule expected in August 2026.
Key Highlights
- Total revenue rose 29% to $26.5 million in Q1 2026.
- Net loss was $19.7 million, or $0.52 per share, in Q1 2026.
- Gross margin was 87% in Q1 2026, compared to 88% in Q1 2025.
- Operating expenses increased 36% to $43.9 million in Q1 2026.
- Ended Q1 2026 with 680 total active accounts.
- Cash, cash equivalents, and marketable securities totaled $141.2 million.
- Raised full-year 2026 revenue guidance to $112 million to $116 million.
- Initiated commercial launch of neonate and pediatric products.